Literature DB >> 3100311

Gastrointestinal absorption of aluminium from single doses of aluminium containing antacids in man.

R Weberg, A Berstad.   

Abstract

Ten subjects with normal renal function were given different single doses of aluminium containing antacids (1, 4, or 8 tablets). The antacid tablets (aluminium content 244 mg tablet-1) were chewed and swallowed either with water, with orange juice, or with citric acid solution. There was a marked increase in serum concentration of aluminium when the antacids was ingested with citric acid (P less than 0.001) or with orange juice (P less than 0.05). When antacids were taken with water, a slight, but significant increase in serum aluminium concentration was seen with 4, but not with 1 or with 8 tablets. Following all doses of antacid, a significant increase in 24 h urinary excretion of aluminium was seen. The estimated absorption of aluminium was 8 and 50 times higher when antacids were taken with orange juice or with citric acid, respectively, than when taken with water. Thus, measurable quantities of aluminium are absorbed from single oral doses of antacids. The absorption is substantially enhanced by concomitant ingestion of citric acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3100311     DOI: 10.1111/j.1365-2362.1986.tb01018.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Geographical associations between aluminium in drinking water and death rates with dementia (including Alzheimer's disease), Parkinson's disease and amyotrophic lateral sclerosis in Norway.

Authors:  T P Flaten
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

3.  The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers.

Authors:  N D Priest; R J Talbot; J G Austin; J P Day; S J King; K Fifield; R G Cresswell
Journal:  Biometals       Date:  1996-07       Impact factor: 2.949

Review 4.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

Review 5.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

6.  Mortality from dementia among gastroduodenal ulcer patients.

Authors:  T P Flaten; E Glattre; A Viste; O Søoreide
Journal:  J Epidemiol Community Health       Date:  1991-09       Impact factor: 3.710

7.  Effects of aluminum sulphate and citric acid ingestion on lipid peroxidation and on activities of superoxide dismutase and catalase in cerebral hemisphere and liver of developing young chicks.

Authors:  C Swain; G B Chainy
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

8.  Aluminum concentrations in tissues of rats: effect of soft drink packaging.

Authors:  J Kandiah; C Kies
Journal:  Biometals       Date:  1994-01       Impact factor: 2.949

Review 9.  Aluminium in over-the-counter drugs: risks outweigh benefits?

Authors:  Claudia M Reinke; Jörg Breitkreutz; Hans Leuenberger
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs.

Authors:  E A Cefali; J C Nolan; W R McConnell; D L Walters
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.